A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis

Genes and Immunity

Volumn 11, Issue 1, 2010, Pages 1-10

  Heckmann, J M ^a   Uwimpuhwe, H ^a   Ballo, R ^a   Kaur, M ^b   Bajic, V B ^b,c   Prince, S ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^c KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

CD55; Complement; Decay accelerating factor; Extraocular muscles; Myasthenia gravis; Regulatory single nucleotide polymorphism

Indexed keywords

DECAY ACCELERATING FACTOR; LUCIFERASE; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL STRAIN COS7; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; DISEASE SEVERITY; DNA FLANKING REGION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOBLAST; MAJOR CLINICAL STUDY; MOUSE; MUTATIONAL ANALYSIS; MYASTHENIA GRAVIS; NEGRO; NONHUMAN; OPHTHALMOPLEGIA; PRIORITY JOURNAL; REPORTER GENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANIMALS; ANTIGENS, CD55; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COMPLEMENT PATHWAY, CLASSICAL; COS CELLS; FEMALE; HUMANS; IMMUNOSUPPRESSION; LIPOPOLYSACCHARIDES; MALE; MICE; MYASTHENIA GRAVIS; PARESIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC;

EID: 75049083553     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2009.61     Document Type: Article

References (54)

1. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis. Ultrastructural and light microscopic localization and electro-physiological correlations. Mayo Clin Proc 1977; 52: 267-280.
2. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002; 110: 1269-1274.
3. Shahashi K, Engel AG, Lambert EH, Howard FM. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropath Exp Neurol 1980; 39: 160-172.
4. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978; 298: 1116-1122.
5. Sahashi K, Engel AG, Lindstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 1978; 37: 212-223.
6. Lennon VA, Seybold ME, Lindstrom J, Cochrane C, Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978; 147: 973-983.
7. Biescker G, Gomez CM. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C5. Immunology 1989; 142: 2654-2659.
8. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996; 71: 173-177.
9. Chamberlain-Banoub J, Neal JW, Mizuno M, Harris CL, Morgan BP. Complement membrane attack is required for end-plate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006; 146: 278-286.
10. Tüzün E, Scott BG, Goloszko E, Higgs S, Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthe-nia gravis. J Immunol 2003; 171: 3847-3854.
11. Ruff RL, Lennon VA. How myasthenia alters the safety factor for neuromuscular transmission. J Neuroimmunol 2008; 201-202: 13-20.
12. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay accelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558-1578.
13. Fujita T, Inoue T, Ogawa K, Iida K, Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166: 1221-1228.
14. Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004; 189: 333-342.
15. Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 2006; 202: 287-293.
16. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 2006; 146: 294-302.
17. Heckmann JM, Owen EP, Little F. Myasthenia gravis in South Africans: racial differences in clinical manifestations. Neuro-muscul Disord 2007; 17: 929-934.
18. Lass JH, Walter EI, Burris TE, Grossniklaus HE, Roat MI, Skelnik DL et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990; 31: 1136-1148.
19. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001; 98: 12062-12067.
20. Post TW, Arce MA, Liszewski MK, Thompson ES, Atkinson JP, Lublin DM. Structure of the gene for human complement protein decay accelerating factor. J Immunol 1990; 144: 740-744.
21. Osuka F, Endo Y, Higuchi M, Suzuki H, Shio Y, Fujiu K et al. Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor. Genomics 2006; 88: 316-322.
22. Coyne KE, Hall SE, Thompson ES, Arce MA, Kinoshita T, Fuijita T et al. Mapping epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 1992; 149: 2906-2913.
23. Brodbeck WG, Kuttner-Kondo L, Mold C, Medof ME. Structure/function studies of human decay-accelerating factor. Immunology 2000; 101: 104-111.
24. Caras IW, Davitz MA, Rhee L, Davitz MA, Rhee L, Weddell G et al. Cloning of decay accelerating factor suggests novel use of splicing to generate two proteins. Nature 1987; 325: 545-548.
25. Moran P, Raab H, Kohr WJ, Caras IW. Glycophospholipid membrane anchor attachment. Molecular analysis of the cleavage/attachment site. J Biol Chem 1991; 266: 1250-1257.
26. Ewulonu UK, Ravi L, Medof ME. Characterization of the decay-accelerating factor gene promoter region. Proc Natl Acad Sci USA 1991; 88: 4675-4679.
27. 0-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression. J Immunol 1993; 150: 151-160.
28. Cauvi DM, Cauvi G, Pollard KM. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1. J Immunol 2006; 177: 3837-3847.
29. Knight JC. Regulatory polymorphisms underlying complex disease traits. J Mol Med 2005; 83: 97-109.
30. Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Extraocular muscle susceptibility to myasthenia gravis. Unique immunological environment? Ann N Y Acad Sci 2008; 1132: 220-224.
31. Brivanlou AH, Darnell Jr JE. Signal transduction and the control of gene expression. Science 2002; 295: 813-818.
32. Courey AJ, Holtzman DA, Jackson SP, Tijan R. Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 1989; 59: 827-836.
33. Boisclair YR, Brown AL, Casola S, Rechler MM. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J Biol Chem 1993; 268: 24892-24901.
34. Dusing MR, Wiginton DA. Sp1 is essential for both enhancer-mediated and basal activation of the TATA-less human adenosine deaminase promoter. Nucleic Acids Res 1994; 22: 669-677.
35. Pastinen T, Slavek R, Gurd S, Sammak A, Ge B, Lepage P et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics 2003; 16: 184-193.
36. Udalvo IA, Richardson A, Denys A, Smith C, Ackerman H, Foxwell B et al. Functional consequences of a polymorphism affecting NF-kB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000; 20: 9113-9119.
37. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005; 201: 567-577.
38. Heeger PS, Lalli PN, Lin F, Valujskikh A, Lui J, Muqim N et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530.
39. Soltys J, Kusner L, Young A, Richmonds C, Hatala D, Gong B et al. Novel complement inhibitor limits severity of experimental myasthenia gravis. Ann Neurol 2009; 65: 67-75.
40. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80: 5066-5070.
41. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983; 80: 5430-5434.
42. Lublin DM, Mallinson G, Poole J, Reid ME, Thompson ES, Ferdman BR et al. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood 1994; 84: 1276-1282.
43. Taniguchi H, Lowe CE, Cooper JD, Smyth D, Bailey R et al. Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type I diabetes. BMC Genetics 2006; 7: 22-31.
44. Christmas SE, de la Mata Espinosa CT, Halliday D, Buxton CA, Cummerson A, Johnson PM. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes. Immunology 2006; 119: 522-528.
45. Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA et al. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and-independent mechanisms. Am J Path 2007; 170: 1258-1266.
46. Zhou Y, Gong B, Lin F, Rother RP, Medof ME, Kaminski HJ. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 2007; 179: 8562-8567.
47. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243. (Pubitemid 44427447)
48. 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9: 431-438.
49. AACT method. Methods 2001; 25: 402-408.
50. Wong ML, Medrano JF. Real-time PCR for mRNA quantification. Biotechniques 2005; 39: 75-85.
51. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006; 1: 1559-1582.
52. Iborra A, Mayorga M, Llobet N, Martinez P. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells. Cell Immunol 2003; 223: 46-51.
53. 2 regulates the complement inhibitor CD55/ decay-accelerating factor in colorectal cancer. J Biol Chem 2005; 280: 476-483.
54. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucl Acids Res 2006; 34(Database issue): D108-D110.